Richard Mulligan

Richard Charles Mulligan is the founder of Sarissa Capital Management LP, founded in 2013, where the title held was Senior Managing Director & Founding Partner from 2013 to 2016.
Current jobs include Vice Chairman at Kadmon Pharmaceuticals LLC since 2010, Vice Chairman at Sana Biotechnology, Inc. since 2018, Director-Harvard Gene Therapy Initiative at Harvard Medical School since 1996, Independent Director at International Flavors & Fragrances, Inc. starting in 2025, Member at US Food & Drug Administration, and Member-Supervisory Board at Biogen GmbH since 2009.
Former jobs include Vice Chairman at Enzon Pharmaceuticals, Inc. from 2011 to 2013, Director at Forest Laboratories, Inc., Director at ImClone LLC from 2006 to 2008, Independent Director at Biogen, Inc. from 2009 to 2023, Director at Genzyme Corp., Independent Director at Cellectis SA, Director at Biogen Idec New Ventures, Inc., Independent Director at Bausch Health Cos., Inc. from 2022 to 2026, Portfolio Manager at Icahn Capital LP from 2017 to 2018, Member at Whitehead Institute for Biomedical Research, Chief Scientific Officer at Somatix Therapy Corp., and Professor-Molecular Biology at Massachusetts Institute of Technology from 1991 to 1996.
Education includes undergraduate degree from Massachusetts Institute of Technology and doctorate from Stanford University School of Medicine.